Serum albumin as a significant prognostic factor for patients with gastric carcinoma

Annals of Surgical Oncology

Volumn 14, Issue 2, 2007, Pages 381-389

  Oñate Ocaña, Luis F ^a   Aiello Crocifoglio, Vincenzo ^a   Gallardo Rincón, Dolores ^a   Herrera Goepfert, Roberto ^a   Brom Valladares, Rocío ^a   Carrillo, José F ^a   Cervera, Eduardo ^a   Mohar Betancourt, Alejandro ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Adenocarcinoma; Prognostic factor; Serum albumin; Stomach neoplasm

Indexed keywords

ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HAZARD ASSESSMENT; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN DETERMINATION; SAMPLE SIZE; STOMACH CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; SERUM ALBUMIN; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33846574720     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9093-x     Document Type: Article

References (37)

1. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: Review and considerations for future directions. Ann Surg 2005; 241:27-39.
2. Oñate-Ocaña LF. Epidemiology note: Gastric cancer in Mexico. Gastric Cancer 2001; 4:162-4.
3. Dirección General de Epidemiología, Asociaciòn Mexicana de Patòlogos and Instituto Nacional de Cancerología: Registro Histopatológico de Neoplasias Malignas: resultados 1998-1999. México D.F. México: Dirección General de Epidemiología, 1999.
4. Oñate-Ocaña LF, Aiello-Crocifoglio V, Mondragón- Sánchez R, Ruiz Molina JM, Gallardo-Rincón D. Prognostic factors in 793 cases of gastric cancer in an oncologic referral center. Rev Gastroenterol Mex 1999; 64:114-21.
5. Greene FL, Page DL, Fleming ID, Fritz A, Balch CMAmerican Joint Committee on Cancer. AJCC Cancer Staging Manual, Sixth edition Berlin Heidelberg New York: Springer; 2002.
6. Peeters KC, Kattan MW, Hartgrink HH, Kranenbarg EK, Karpeh MS, Brennan MF, van de Velde CJ. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 2005; 103:702-7.
7. Bollschweiler EH, Monig SP, Hensler K, Baldus SE, Maruyama K, Holscher AH. Artificial neural network for prediction of lymph node metastases in gastric cancer: a phase II diagnostic study. Ann Surg Oncol 2004; 11:506-11.
8. Goldwasser P, Felman J. Association of Serum Albumin and Mortality Risk. J Clin Epidemiol 1997; 50:693-703.
9. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Elliot P, Ueshima Hfor the NIPPON DATA80 Research Group. A combination of serum low albumin and above-average cholesterol level was associated with excess mortality. J Clin Epidemiol 2004; 57:1188-95.
10. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-59.
11. Paniagua R, Amato D, Vonesh E, Guo A, Mujais S. Mexican Nephrology Collaborative Study Group: Health-related quality of life predicts outcomes but is not affected by peritoneal clearance. The ADEMEX trial. Kidney Int 2005; 67:1093-104.
12. Jinks MF, Kelly CA. The pattern and significance of abnormal liver function tests in community-acquired pneumonia. Eur J Intern Med 2004; 15:436-40.
13. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005; 95:199-203.
14. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system - risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-36.
15. Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54:419-25.
16. Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. Prognostic scoring in colorectal cancer liver metastases: Development and validation. Arch Surg 2005; 140:183-9.
17. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-20.
18. Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA. Is serum albumin an independent predictor of survival in patients with breast cancer? J Parent Enteral Nutr 2003; 27:10-5.
19. Oñate-Ocaña LF, Aiello-Crocifoglio V, Mondragón- Sánchez R, Ruiz-Molina JM. Survival benefit of D2 lympadenectomy in patients with gastric adenocarcinoma. Ann Surg Oncol 2000; 7:210-7.
20. Oñate-Ocaña LF, Cortés-Cárdenas SA, Aiello-Crocifoglio V, Mondragón-Sánchez R, Ruiz-Molina JM. Preoperative multivariate prediction of morbidity after gastrectomy for adenocarcinoma. Ann Surg Oncol 2000; 7:281-8.
21. Moss AA. Computed tomography in the staging of gastrointestinal carcinoma. Radiol Clin North Am 1982; 20:761-80.
22. Japanese Research Society for Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Jpn J Surg 1981; 11:127-45.
23. Duly EB, Grimason S, Grimason P, Barnes G, Trinick TR. Measurement of serum albumin by capillary zone electrophoresis, bromocresol green, bromocresol purple, and immunoassay methods. J Clin Pathol 2003; 56:780-1.
24. Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Statist Med 2000; 19:113-32.
25. Kaplan EL, Meier PM. Nonparametric estimation from incomplete observations. J Am Stat Soc 1958; 53:457-81.
26. Bland JM, Altman DG. The logrank test. Br Med J 2004; 328:1073.
27. Feinstein AR. Proportional hazards analysis (Cox regression). In: Multivariable analysis: An introduction. New Haven: Yale University Press (1996) pp 370-97.
28. Lien YC, Hsieh CC, Wu YC, et al. Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg 2004; 8:1041-8.
29. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8:86-94.
30. Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology 1988; 8:385-401.
31. Chojkier M. Inhibition of albumin synthesis in chronic diseases. J Clin Gastroenterol 2005; 39(suppl 2):S142-S146.
32. Fearon KCH, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acutephase protein synthesis. Ann Surg 1998; 227:249-54.
33. Forones NM, Mandowsky SV, Lourenco LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology 2001; 48:1199-201.
34. Bauer J, Herrmann F. Interleukin-6 in clinical medicine. Ann Hematol 1991; 62:203-10.
35. Ashizawa T, Okada R, Suzuki Y, et al. Clinical significance of interleukin-6 in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005; 8:124-31.
36. Krijgsman B, Papadakis JA, Ganotakis ES, Mikhailidis DP, Hamilton G. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: Bilirubin and albumin. Int Angiol 2002; 21:44-52.
37. Era S, Kuwata K, Imai H, Nakamura K, Hayashi T, Sogami M. Age-related change in redox state of human serum albumin. Biochim Biophys Acta 1995; 1247:12-6.